Business
Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022
MONTREAL and CHARLOTTE, N.C., Oct. 25, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the
About this update from Milestone Pharmaceuticals Inc.
[{"type":"text","content":"MONTREAL and CHARLOTTE, N.C., Oct. 25, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that data from the Phase 3 RAPID clinical trial of self-administered etripamil in patients with paroxysmal supraventricular tachycardia (PSVT) in the at-home setting will be featured during a Late-Breaking Clinical Trials session at the American Heart Association Scientific Sessions 2022 taking place November 5-7, 2022 in Chicago, IL and virtually. Etripamil, a new chemical entity, is Milestone's lead investigational product.\nThe Late-Breaker presentation details are:\nTitle: Self-Administered Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis From the RAPID StudyPresentation number: 19625Session number: LBS.08Session Title: Late-Breaking Science: Treating Atrial and Supraventricular ArrhythmiasPresenter: James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital, on behalf of Bruce Stambler, M.D., F.H.R.S, Director of Cardiac Arrhythmia Research and Education, Piedmont Heart Institute, Atlanta, GA and all co-authors.Date and Time: Monday, November 7, 2022 from 11:13-11:23 a.m. CT\nIn addition, data from the previously completed Phase 3 NODE-301 trial will be featured in a poster presentation session, the details of which are:\nTitle: Patient-Reported Treatment Satisfaction in Etripamil-Mediated Conversion of Supraventricular Tachycardia to Sinus Rhythm: Results From the NODE-301 StudyPresentation Number: MO4023Session Title: Benefits and Risks Associated with Arrhythmia ManagementPresenter: James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital, on behalf of all co-authors.Date and Time: Monday, November 7, 2022 from 11:00 a.m.-12:00 p.m. CT\nAbout Paroxysmal Supraventricular Tachycardia\nParoxysmal supraventricular tachycardia (PSVT) is a condition affecting approximately two million Americans that is characterized by intermittent episodes of a rapid heartbeat that starts and stops suddenly. Episodes of supraventric...